Joint Corp. (The) (JYNT)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$8.09-1.22%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
The Joint Corp. aims to open 30 to 35 new franchised clinics in 2026. It targets revenue between $519 million and $552 million this year. The company has a history of earnings beats and positive M&A activity. These factors support steady growth and expansion.
Revenue growth may slow as recent guidance was lowered for 2025. The company faces elevated risk with volatile management and thin free cash flow yield. High valuation multiples could pressure returns if growth disappoints.
The market expects about 6% revenue growth over the next year. Our fair value estimate is slightly above current price, but the 3- and 5-year growth implied by the price is unjustified given forecast declines.
Breaks if: new franchised clinic openings fall below 30 in 2026
Grow the number of new franchised clinic openings, excluding refranchised clinics, targeting 22 to 35 new openings in 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story as JYNT works to improve its business model by refranchising. The current thesis state is intact, but recent performance has been mixed, reflecting volatility in management execution.
The market appears to price in a durable premium compared to peers, indicating that expectations are somewhat elevated. However, the valuation is considered unjustified given the mixed recent performance and the company's current challenges.
Fundamentals may face pressure due to recent earnings misses and a cautious outlook on new franchised clinic openings. The probability of missing expectations is notable, especially given the company's smaller size and recent mixed results.
The thesis hinges on management's ability to execute its refranchising strategy and maintain system-wide sales guidance. Additionally, the performance of sector bellwethers and overall economic conditions will be crucial in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a significant miss. This miss raises concerns about the company's future performance. Management is also facing challenges with frequent changes. These factors contribute to a less favorable outlook for JYNT.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. The Company revised its 2026 new franchised clinic openings guidance downward from 30-35 in 2026-Q1 to 22-26 in 2026-Q2, reflecting a more cautious growth outlook. This indicates limited progress on expanding new franchised clinics compared to prior expectations.
“New franchised clinic openings, excluding refranchised clinics, are now expected to be in the range of 22 to 26 in 2026.”
“New franchised clinic openings, excluding refranchised clinics, are expected to be in the range of 30 to 35 in 2026.”
Breaks if: management execution deteriorates causing missed targets or strategy shifts
Breaks if: annual revenue falls below $519 million in 2026
Over the next 1 to 3 years, JYNT's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.